Literature DB >> 8973795

Single-channel evidence for glycine and NMDA requirement in NMDA receptor activation.

M C Currás1, B S Pallotta.   

Abstract

N-Methyl-D-aspartate (NMDA) receptor dose-response relationships that are based on macroscopic currents suggest that NMDA and a different agonist molecule, glycine, must together activate the channel. Since single-channel recordings have a much higher resolution than whole-cell currents, they provide a highly sensitive test for the absolute requirement of NMDA channel opening for glycine. Rapid application of 10-300 microM NMDA to outside-out patches from cultured cortical neurons evoked substantial single-channel activity in the absence of added glycine. However, in the presence of a high affinity and highly selective glycine-site antagonist, 5,7-dichlorokynurenate (DCK), NMDA failed to evoke any openings on its own. Channel openings could not be produced by saturating concentrations of NMDA (up to 1 mM) but were evoked when glycine was added to the test solution. Glycine alone (up to 100 microM) was similarly ineffective in the continuous presence of D(-)-2-amino-5-phosphonovaleric acid (D-APV), an NMDA-site antagonist. Reversal of antagonist blockade by the appropriate ligand (glycine or NMDA) and the normal appearance and duration of channel openings evoked in the presence of either antagonist ruled out open channel block. These single-channel data confirm the hypothesis that both NMDA and glycine are coagonists of the NMDA receptor. Furthermore, the coagonist requirement increases the potential targets for therapeutic drugs aimed at blocking the pathologies resulting from overactivation of NMDA receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8973795     DOI: 10.1016/s0006-8993(96)00845-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Modulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in mice.

Authors:  Philipp Singer; Detlev Boison; Hanns Möhler; Joram Feldon; Benjamin K Yee
Journal:  Eur Neuropsychopharmacol       Date:  2010-07-19       Impact factor: 4.600

Review 2.  Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.

Authors:  Meredith J Noetzel; Carrie K Jones; P Jeffrey Conn
Journal:  Discov Med       Date:  2012-11       Impact factor: 2.970

3.  Simultaneous efflux of endogenous D-ser and L-glu from single acute hippocampus slices during oxygen glucose deprivation.

Authors:  Daniel L Kirschner; Ann L Wilson; Kelly L Drew; Thomas K Green
Journal:  J Neurosci Res       Date:  2009-09       Impact factor: 4.164

4.  Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia.

Authors:  Meghan Elizabeth Goldstein; Valerie Margaret Anderson; Avinesh Pillai; Robert R Kydd; Bruce R Russell
Journal:  Int J Neuropsychopharmacol       Date:  2015-01-20       Impact factor: 5.176

Review 5.  Molecular imaging as a guide for the treatment of central nervous system disorders.

Authors:  Euitae Kim; Oliver D Howes; Shitij Kapur
Journal:  Dialogues Clin Neurosci       Date:  2013-09       Impact factor: 5.986

Review 6.  Enhancing NMDA Receptor Function: Recent Progress on Allosteric Modulators.

Authors:  Lulu Yao; Qiang Zhou
Journal:  Neural Plast       Date:  2017-01-09       Impact factor: 3.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.